JSS Sustainable Equity - Future Health P EUR acc

Reference Data

ISIN LU2041625141
Valor Number 49498037
Bloomberg Global ID
Fund Name JSS Sustainable Equity - Future Health P EUR acc
Fund Provider J. Safra Sarasin Investmentfonds AG Basel, Switzerland
Phone: +41 58 317 44 44
Web: www.jsafrasarasin.com
Fund Provider J. Safra Sarasin Investmentfonds AG
Representative in Switzerland J. Safra Sarasin Investmentfonds AG
Basel
Phone: +41 58 317 44 00
Distributor(s) Bank J. Safra Sarasin AG
Basel
Phone: +41 58 317 44 00
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The investment objective of the fund is to achieve long-term capital growth. The Reference Currency of the Sub-Fund is the US Dollar (USD).
Peculiarities

Fund Prices

Current Price * 92.98 EUR 21.05.2025
Previous Price * 95.11 EUR 20.05.2025
52 Week High * 108.58 EUR 30.08.2024
52 Week Low * 88.80 EUR 10.04.2025
NAV * 92.98 EUR 21.05.2025
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 121,663,720
Unit/Share Assets *** 5,757,970
Trading Information SIX

Performance

YTD Performance -8.77% 31.12.2024
21.05.2025
YTD Performance (in CHF) -9.23% 31.12.2024
21.05.2025
1 month +2.76% 22.04.2025
21.05.2025
3 months -12.74% 21.02.2025
21.05.2025
6 months -8.89% 21.11.2024
21.05.2025
1 year -10.35% 21.05.2024
21.05.2025
2 years -13.07% 22.05.2023
21.05.2025
3 years -13.37% 23.05.2022
21.05.2025
5 years -5.73% 22.05.2020
21.05.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

UnitedHealth Group Inc 9.27%
Eli Lilly and Co 6.74%
Sanofi SA 6.60%
Danaher Corp 6.30%
Gilead Sciences Inc 5.20%
Intuitive Surgical Inc 4.51%
Boston Scientific Corp 4.22%
Johnson & Johnson 4.17%
Novo Nordisk AS Class B 3.87%
argenx SE 3.71%
Last data update 31.03.2025

Cost / Risk

TER 1.99%
TER date 31.10.2024
Performance Fee ***
PTR
Max. Management Fee *** 2.00%
Ongoing Charges *** 1.97%
SRRI ***
SRRI date *** 30.04.2025

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)